Management of anti-thrombin III deficiency during pregnancy without administration of anti-thrombin III.
We report a patient with hereditary antithrombin III deficiency who was successfully treated with heparin throughout pregnancy. Functional antithrombin III levels fell to 0.32 U/ml during heparin treatment, but it was possible to achieve a heparin effect, measured by the activated partial thromboplastin time, thrombin clotting time and heparin assay with subcutaneous heparin in doses of 30,000 U to 35,000 U/24 hours. This achieve an long term heparin effect was obtained without the need for antithrombin III infusions.
D000293:Adolescent; D000328:Adult; D000990:Antithrombin III / Q000032:analysis / Q000627:therapeutic use; D020152:Antithrombin III Deficiency; D001778:Blood Coagulation Disorders / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000188:drug therapy / Q000235:genetics*
D000990:Antithrombin III; D006493:Heparin